Artuner Varlibaş
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Artuner Varlibaş has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Aydın Çifci
Department of Internal Medicine, Faculty of Medicine, Kirikkale University, Kirikkale, Turkey
2 shared publications - Aykut Haciömeroğlu
Department of Internal Medicine, Faculty of Medicine, Kirikkale University, Kirikkale, Turkey
1 shared publication - Duygu Felek
Department of Internal Medicine, Faculty of Medicine, Yozgat Bozok University, 66100 Yozgat, Türkiye
1 shared publication - Ercan Yuvanç
Kirikkale Universitesi
1 shared publication - Erdal Yilmaz
Department of Urology, Kirikkale University Medical Faculty, Kirikkale, Turkey
1 shared publication - Gül Kırtıl
Department of Medical Biochemistry, Health Sciences University, Ankara Training and Research Hospital, 06230 Ankara, Turkey
1 shared publication
Latest Publications
- Open Access
- 22 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (21) , e49023
Fibromyalgia, quality of life, and thiol/disulfide homeostasis in patients undergoing hemodialysis: A multicenter cross-sectional study
Fibromyalgia syndrome (FMS) is a common but frequently overlooked cause of chronic pain in patients with chronic kidney disease, particularly those undergoing hemodialysis (HD). In addition to its impact on quality of life (QoL), FMS may be associated with oxidative stress pathways involved in chronic kidney disease pathophysiology. However, the relationship between FMS and thiol/disulfide homeostasis in HD patients remains unclear. This study examined the association between FMS, QoL, and thiol/disulfide parameters in a multicenter HD population. In this multicenter cross-sectional study, 126 HD patients (66 with FMS and 60 without FMS) from 2 dialysis centers in Turkey were evaluated between July and December 2024. FMS was diagnosed using the 2016 American College of Rheumatology criteria. Demographic data, laboratory parameters, QoL measures (short form-36 [SF-36], Fibromyalgia Impact Questionnaire [FIQ], Brief Illness Perception Questionnaire), and oxidative stress markers (native thiol, total thiol, disulfide, and related ratios) measured by automated spectrophotometry were analyzed. Group comparisons were performed using appropriate statistical tests. Correlations were assessed using Spearman analysis. Multivariable binary logistic regression was conducted to identify variables independently associated with FMS. Post hoc power analysis demonstrated adequate statistical power (87.3%, α = 0.05). Native thiol (242.35 ± 40.45 vs 225.36 ± 40.01 μmol/L, P = .019), total thiol (284.39 ± 46.60 vs 264.76 ± 46.29 μmol/L, P = .019), and disulfide (21.02 ± 3.74 vs 19.70 ± 3.62 μmol/L, P = .047) levels were higher in patients with FMS, whereas thiol/disulfide ratios did not differ between groups. FMS patients had significantly higher FIQ scores and lower SF-36 domain scores, indicating poorer QoL. Weak correlations were observed between native thiol and FIQ ( r = 0.202) and between total thiol and SF-36 mental health (ρ = −0.242). In multivariable analysis, total thiol remained independently associated with FMS (OR = 1.009, P = .023), although explained variance was modest (Nagelkerke R 2 = 0.058). FMS in HD patients is associated with impaired QoL and modest alterations in thiol-related oxidative parameters without a shift in thiol/disulfide ratios. These findings should be interpreted cautiously given the cross-sectional design. Prospective studies are needed to clarify underlying mechanisms.
- 22 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (21) , e49023
Open AccessFibromyalgia, quality of life, and thiol/disulfide homeostasis in patients undergoing hemodialysis: A multicenter cross-sectional study
Fibromyalgia syndrome (FMS) is a common but frequently overlooked cause of chronic pain in patients with chronic kidney disease, particularly those undergoing hemodialysis (HD). In addition to its impact on quality of life (QoL), FMS may be associated with oxidative stress pathways involved in chronic kidney disease pathophysiology. However, the relationship between FMS and thiol/disulfide homeostasis in HD patients remains unclear. This study examined the association between FMS, QoL, and thiol/disulfide parameters in a multicenter HD population. In this multicenter cross-sectional study, 126 HD patients (66 with FMS and 60 without FMS) from 2 dialysis centers in Turkey were evaluated between July and December 2024. FMS was diagnosed using the 2016 American College of Rheumatology criteria. Demographic data, laboratory parameters, QoL measures (short form-36 [SF-36], Fibromyalgia Impact Questionnaire [FIQ], Brief Illness Perception Questionnaire), and oxidative stress markers (native thiol, total thiol, disulfide, and related ratios) measured by automated spectrophotometry were analyzed. Group comparisons were performed using appropriate statistical tests. Correlations were assessed using Spearman analysis. Multivariable binary logistic regression was conducted to identify variables independently associated with FMS. Post hoc power analysis demonstrated adequate statistical power (87.3%, α = 0.05). Native thiol (242.35 ± 40.45 vs 225.36 ± 40.01 μmol/L, P = .019), total thiol (284.39 ± 46.60 vs 264.76 ± 46.29 μmol/L, P = .019), and disulfide (21.02 ± 3.74 vs 19.70 ± 3.62 μmol/L, P = .047) levels were higher in patients with FMS, whereas thiol/disulfide ratios did not differ between groups. FMS patients had significantly higher FIQ scores and lower SF-36 domain scores, indicating poorer QoL. Weak correlations were observed between native thiol and FIQ ( r = 0.202) and between total thiol and SF-36 mental health (ρ = −0.242). In multivariable analysis, total thiol remained independently associated with FMS (OR = 1.009, P = .023), although explained variance was modest (Nagelkerke R 2 = 0.058). FMS in HD patients is associated with impaired QoL and modest alterations in thiol-related oxidative parameters without a shift in thiol/disulfide ratios. These findings should be interpreted cautiously given the cross-sectional design. Prospective studies are needed to clarify underlying mechanisms.
- Open Access
- 7 April 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (7) , 777
The Diagnostic Value of Soluble Triggering Receptor Expressed on Myeloid Cells for Patients with Acute Stone Pyelonephritis
Soluble triggering receptor expressed on myeloid cells (sTREM-1) is a new biomarker that can be used for the diagnosis and monitoring of urinary system infections. This study aimed to evaluate the diagnostic performance of serum sTREM-1 in patients with a diagnosis of acute stone pyelonephritis (ASP). This prospective study included 46 patients with a diagnosis of ASP and a control group of 23 individuals without urinary system infection. Blood samples were taken from participants upon hospital admission, and basal serum sTREM-1 levels were analyzed using the ELISA method. Serum sTREM-1 concentrations were measured after treatment of ASP patients. Basal leukocyte counts, C-reactive protein (CRP) levels, procalcitonin (PCT), and sTREM-1 (98.6 vs. 68.4 pg/mL, p < 0.001) levels were higher in the ASP group compared to the control group. After treatment, the median leukocyte counts, PCT, and sTREM-1 levels decreased and were similar to those of the control group. The median CRP level also decreased after treatment, but it remained higher than that of the control group. In predicting patients with ASP, the baseline sTREM-1 exhibited a sensitivity of 74.6% and a specificity of 78.2%, while its diagnostic performance was lower than that of leukocyte counts, CRP, and PCT. Despite the findings that levels of sTREM-1 were higher upon hospital admission in patients with ASP and significantly decreased after treatment, the utility of sTREM-1 as a biomarker for predicting patients with ASP remains constrained when compared to established inflammatory markers.
- 7 April 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (7) , 777
Open AccessThe Diagnostic Value of Soluble Triggering Receptor Expressed on Myeloid Cells for Patients with Acute Stone Pyelonephritis
Soluble triggering receptor expressed on myeloid cells (sTREM-1) is a new biomarker that can be used for the diagnosis and monitoring of urinary system infections. This study aimed to evaluate the diagnostic performance of serum sTREM-1 in patients with a diagnosis of acute stone pyelonephritis (ASP). This prospective study included 46 patients with a diagnosis of ASP and a control group of 23 individuals without urinary system infection. Blood samples were taken from participants upon hospital admission, and basal serum sTREM-1 levels were analyzed using the ELISA method. Serum sTREM-1 concentrations were measured after treatment of ASP patients. Basal leukocyte counts, C-reactive protein (CRP) levels, procalcitonin (PCT), and sTREM-1 (98.6 vs. 68.4 pg/mL, p < 0.001) levels were higher in the ASP group compared to the control group. After treatment, the median leukocyte counts, PCT, and sTREM-1 levels decreased and were similar to those of the control group. The median CRP level also decreased after treatment, but it remained higher than that of the control group. In predicting patients with ASP, the baseline sTREM-1 exhibited a sensitivity of 74.6% and a specificity of 78.2%, while its diagnostic performance was lower than that of leukocyte counts, CRP, and PCT. Despite the findings that levels of sTREM-1 were higher upon hospital admission in patients with ASP and significantly decreased after treatment, the utility of sTREM-1 as a biomarker for predicting patients with ASP remains constrained when compared to established inflammatory markers.